retatrutide type 2 diabetes trial results 2024 Lilly's triple agonist achieves 16.8% weight loss in phase 3 Retatrutide Results: 28.3% Weight Loss

Rare but serious events such as pancreatitis and gallbladder disease exist

Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodrguez,

[1] Its mechanism promotes insulin secretion, slows gastric emptying, and reduces appetite, leading to notable improvements in glycaemic control and body weight reduction

Ozempic is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes, not weight management

View our full research compounds catalog

Hormonal imbalances can make weight maintenance feel like an uphill battle, but with our Bioidentical Hormone Replacement Therapy (HRT), we can restore balance and support your journey